Trabectedin, Bevacizumab, Platinum Chemotherapy Combo May Work, But Safety a Concern, Study Finds

Trabectedin, Bevacizumab, Platinum Chemotherapy Combo May Work, But Safety a Concern, Study Finds
Women with ovarian cancer who are partially sensitive to platinum-based chemotherapy may benefit from a new combination therapy — but safety concerns need to be addressed first, a study suggests. The new study proposes a combination of trabectedin and bevacizumab with platinum-based chemotherapy for these patients, whose disease relapsed within six to 12 months after treatment. Titled "Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer," the study was published in the British Journal of Cancer. Trabectedin, marketed as Yondelis for the treatment of fat and smooth muscle tissue cancers, is a cancer-killing compound that works both by inhibiting the division of cancer cells and by modifying the cellular environment inside tumors. Bevacizumab — trade names Avastin and Mvasi — is another cancer treatment that works by inhibiting the tumor's blood supply. Preclinical data have suggested that these treatments could synergize with each other and with platinum-based therapy, but these
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *